Latest news with #Ginkgo
Yahoo
21-05-2025
- Business
- Yahoo
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation. Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting and corporate finance leadership experience. Prior to his role at Ginkgo, Mr. Coen was the Corporate Vice President and Corporate Controller for Charles River Laboratories, a publicly held global contract research organization for pharmaceutical and biotechnology companies, governmental agencies and leading academic institutions, with approximately 20,000 employees across 150 locations in over 20 countries and annual revenues of approximately $4.0 billion. Prior to that, Mr. Coen served in accounting and finance leadership roles in the technology and medical device industries after spending more than 17 years in the audit practice at Deloitte & Touche LLP. "We thank Mark for his dedicated service to the Company and his leadership of the finance team through many transformational phases at Ginkgo and wish him well in his next opportunity," said Jason Kelly, co-founder and CEO of Ginkgo Bioworks. "I'm excited to elevate Steve to his new role stewarding the finance and accounting functions and we're fortunate to have the continuity of building on his experience at Ginkgo the past two years." "It has been a privilege to work alongside the leadership team and all the talented Bioworkers across Ginkgo," said Mr. Dmytruk. "I am deeply grateful for the opportunity to have contributed to Ginkgo's mission of making biology easier to engineer, and I have full confidence in Steve and the finance team to continue driving the Company's financial vision forward." "Mark has built a high-performing finance organization and laid the groundwork for Ginkgo to continue driving toward our cost reduction targets and our goal of reaching Adjusted EBITDA breakeven by the end of 2026," said Mr. Coen. "I've greatly enjoyed working with Mark over the past two years and am ready to build upon the financial vision and strategy he has laid out." Mr. Coen earned a B.S. in Accounting and an A.S. in Management from Bentley University and is a Certified Public Accountant in Massachusetts. About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. GINKGO BIOWORKS INVESTOR CONTACT:investors@ GINKGO BIOWORKS MEDIA CONTACT:press@ Forward-Looking Statements of Ginkgo BioworksThis press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the transition of our chief financial officer and the timing for attaining Adjusted EBITDA breakeven. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith, (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies and (xiv) challenges and uncertainties related to management transitions. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. View original content to download multimedia: SOURCE Ginkgo Bioworks Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
Alto Introduces Ginkgo REIT Inc. on Alto Marketplace, Expanding Opportunities in Private Real Estate
NASHVILLE, TN / / May 20, 2025 / Alto, an alternative asset investment platform that enables individuals to invest in private markets using retirement funds, has introduced Ginkgo REIT Inc. on the Alto Marketplace. Joining the platform is part of Ginkgo REIT's strategy to expand access to its professionally managed, income-focused multifamily real estate offering for accredited investors using self-directed IRAs (SDIRAs). Ginkgo REIT, managed by Ginkgo Residential, specializes in workforce housing across North and South Carolina-regions experiencing significant population and economic growth. The REIT focuses on acquiring, upgrading, and managing high-quality, attainable communities with an emphasis on long-term value creation and sustainability. "Ginkgo's disciplined investment approach in workforce housing-an increasingly vital sector-offers investors a compelling way to diversify their retirement portfolios, especially in today's uncertain economic climate," said Scott Harrigan, President of Alto. "With ongoing concerns around market volatility, private market investments like Ginkgo's may offer diversification, income potential, and meaningful community impact. We're pleased to highlight Ginkgo's offering on Alto's Marketplace in response to investor appetite for resilient, real estate-backed opportunities."1 Further strengthening its portfolio, Ginkgo Residential recently announced the acquisition of The Preserve at Pine Valley, a 219-unit, garden-style apartment community located in Wilmington, NC. Acquired for $32.1 million in an all-cash joint venture with J.P. Morgan Real Estate Income Trust, Inc. (JPMREIT), the property aligns with Ginkgo's value-add strategy of enhancing workforce housing through thoughtful upgrades and operational improvements. "We're excited to see the positive response from Alto investors and to continue executing on our strategy with acquisitions like The Preserve at Pine Valley," said Bill Green, Principal and Co-CEO of Ginkgo Residential. "Self-directed IRAs provide a powerful avenue for individuals to invest in real estate, and Alto makes that access easier and more streamlined." Since its inception in July 2019, Ginkgo REIT has delivered an average annualized total return of 11.8%, offering investors the potential for stable, tax-efficient income and long-term capital appreciation. As always, past performance is not indicative of future results. Accredited investors can explore Ginkgo REIT Inc. and other exclusive alternative investments today on the Alto Marketplace. 1 It should be noted that while private market investments may offer diversification and income potential, such outcomes are not guaranteed and depend on various risk factors, including market conditions. # About Ginkgo ResidentialGinkgo Residential is a leading provider of attainable, eco-friendly apartment communities across North and South Carolina. The firm specializes in acquiring, renovating, and managing multifamily properties while maintaining affordability for working households. Recognized as a Top Workplace since 2020, Ginkgo Residential emphasizes sustainability, operational efficiency, and strong community engagement. Learn more at About AltoAlto's self-directed IRA platform enables investors to diversify their retirement portfolios with alternative assets like private equity, venture capital, real estate, private credit, and more. Alto acts as the IRA custodian for over $1.7B in assets with 30,000 self-directed IRA investors and supports more than 2,500 issuers who have raised capital on the platform. With minimal paperwork and competitive fees, Alto simplifies access to less-correlated, high-return investments. Users can establish Traditional, Roth, or SEP IRAs and seamlessly invest in private markets. Learn more at Disclosures:The information provided herein is for informational purposes only and is not intended as investment advice or a recommendation to buy or sell any security. This communication does not constitute an offer to sell or a solicitation of an offer to buy any securities, which can only be made through official offering documents, including a private placement memorandum (PPM), subscription agreement, and applicable disclosures. Investments in private placements are speculative, involve a high degree of risk, and are not suitable for all investors. These investments are illiquid, not listed on a securities exchange, and are intended only for investors who do not require immediate liquidity and can bear the risk of loss of their entire investment. There is no guarantee of returns or future performance. Any performance data referenced herein is for illustrative purposes only, reflects historical results, and is not a guarantee of future results. Past performance does not guarantee future outcomes. Forward-looking statements are based on assumptions that may not materialize. This opportunity is available only to Accredited Investors as defined under Rule 501 of Regulation D of the Securities Act of 1933. Investors should carefully review all offering materials and consult with their own legal, tax, and financial advisors before making an investment decision. Securities are offered through Alto Securities, LLC, a registered broker-dealer and member of FINRA and SIPC. Alto Securities does not provide investment advice or make recommendations. Check the background of Alto Securities on FINRA's BrokerCheck. Alto Media ContactHeather ValleCaliber Corporate Advisersalto@ SOURCE: Alto Solutions, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Business Wire
08-05-2025
- Business
- Business Wire
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)-- Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Under the terms of the revised three-year $15 million agreement, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's high-quality DNA products, underscoring the enduring value and reliability of Twist's synthesis capabilities. Ginkgo will receive preferential pricing for DNA products with no required minimum purchase volume. As credit against the agreement signed in 2022, Twist receives licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, while Ginkgo retains the rights to practice the IP transferred to Twist. This strategic acquisition complements Twist's existing comprehensive portfolio of DNA synthesis products, further strengthening its position as a leader in the field. 'Ginkgo has been a trusted customer of Twist since the early days of our synbio offering. As our customers proceed along their journeys and adapt their strategies, we continue to find innovative ways to serve them well,' said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. 'With the updated agreement, we will continue to supply Ginkgo with DNA and also gain IP for writing long DNA, that gives us optionality to incorporate on our own platform.' 'DNA synthesis is a core technology for synthetic biology and we're happy to combine some of our long DNA technology with Twist to hopefully see more and varied offerings in the market,' said Jason Kelly, CEO of Ginkgo Bioworks. 'Twist has been an amazing and close partner over many years for Ginkgo and this updated agreement enables us to keep that close relationship while having more flexibility in when and how we order DNA from Twist.' About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential benefits of the arrangement with Ginkgo. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Yahoo
08-05-2025
- Business
- Yahoo
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums SOUTH SAN FRANCISCO, Calif. & BOSTON, May 08, 2025--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. Under the terms of the revised three-year $15 million agreement, Ginkgo will continue to be a valued customer of Twist and will prepay annually for orders of Twist's high-quality DNA products, underscoring the enduring value and reliability of Twist's synthesis capabilities. Ginkgo will receive preferential pricing for DNA products with no required minimum purchase volume. As credit against the agreement signed in 2022, Twist receives licenses and assignments for certain long DNA and other technology as well as related reagents to complement its existing DNA synthesis portfolio of products, while Ginkgo retains the rights to practice the IP transferred to Twist. This strategic acquisition complements Twist's existing comprehensive portfolio of DNA synthesis products, further strengthening its position as a leader in the field. "Ginkgo has been a trusted customer of Twist since the early days of our synbio offering. As our customers proceed along their journeys and adapt their strategies, we continue to find innovative ways to serve them well," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "With the updated agreement, we will continue to supply Ginkgo with DNA and also gain IP for writing long DNA, that gives us optionality to incorporate on our own platform." "DNA synthesis is a core technology for synthetic biology and we're happy to combine some of our long DNA technology with Twist to hopefully see more and varied offerings in the market," said Jason Kelly, CEO of Ginkgo Bioworks. "Twist has been an amazing and close partner over many years for Ginkgo and this updated agreement enables us to keep that close relationship while having more flexibility in when and how we order DNA from Twist." About Ginkgo Bioworks Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. About Twist Bioscience Corporation At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts. Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit Follow us on LinkedIn | X | YouTube | Instagram | Bluesky Twist Bioscience Legal Notice Regarding Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential benefits of the arrangement with Ginkgo. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. View source version on Contacts TWIST CONTACTS: For Investors: Angela BittingSVP, Corporate Affairs925-202-6211abitting@ For Media: Amanda HoulihanCommunications Manager774-265-5334ahoulihan@ GINKGO CONTACTS: For Investors: investors@ For Media: press@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-04-2025
- Business
- Yahoo
Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors
Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors. The achievement grants Ginkgo with additional equity in Phytolon, and paves the way to explore further collaborations in the field of natural food colors. YOKNE'AM ILLIT, Israel and BOSTON, April 30, 2025 /PRNewswire/ -- Phytolon, a biotech-foodtech startup that offers natural food colors via fermentation of baker's yeast, and Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced the successful completion of the second development milestone of their multi-product collaboration to produce natural food colors and the resulting distribution of an equity milestone to Ginkgo. The collaboration, which started in 2022, consists of development of yeast strains to produce two natural colors, aimed at offering the food industry vibrant, fully functional replacements to synthetic dyes under strong regulatory and legislation pressure. Artificial food dyes are under growing pressure in the U.S., driven by regulatory action and rising health concerns. Health and Human Services Secretary Robert F. Kennedy, Jr. has made removal of synthetic colors a priority, and FDA Commissioner Marty Makary has announced an initiative to eliminate synthetic colors from the US food supply by the end of 2026, if not sooner. The FDA has already banned FD&C Red No. 3 due to cancer risks, and a growing number of states have passed or proposed bans on artificial dyes, especially in school meals. This momentum is accelerating the industry's shift toward natural color alternatives. After achieving the first development milestone (in early 2024) that unlocked the entire yellow-to-purple spectrum, Ginkgo leveraged its strong AI modeling expertise and its high-throughput screening platform to deliver strains with nearly 3-times higher production efficiency, enabling Phytolon to develop high-quality formulations that successfully address the desired coloring standards in multiple food categories such as baked goods, snacks seasoning, toppings & icings, confectionaries, dairy yogurts, and ice creams & frozen novelties. Moreover, the improved production efficiency drives a significant reduction in the production costs and carbon footprint. Phytolon's fermentation-based manufacturing process requires less energy and capital investment to reach high coloring efficiency compared with benchmark natural colors that rely on farming and extensive post-processing. Phytolon's "Beetroot Red" & "Prickly Pear Yellow" are expected to be available in U.S. markets upon approval by the FDA. Upon meeting the second development milestone, Ginkgo will receive additional equity in Phytolon, reaping new benefits from the growing Ginkgo–Phytolon partnership and planting the seeds for follow-up projects that amplify Phytolon's sustainable and cost-efficient offerings to the food coloring sector and the entire food industry. Wissam Mansour, Phytolon's Chief Product Officer, commented, "This is an unprecedented opportunity. The vibrant colors Phytolon is now poised to deliver to customers will allow the food industry to explore the full potential of natural and healthy beet and prickly pear pigments that have never before been readily available with such purity and quality." Jennifer Wipf, Ginkgo's General Manager of Discovery & Manufacturing Solutions, commented, "It has been a pleasure to work alongside our partners at Phytolon to help bring their colorful products to market. We tapped many of Ginkgo's cell programming capabilities to deliver "Beetroot Red" & "Prickly Pear Yellow" production strains and processes that make possible an entire palette of food colors. We look forward to continuing to work with Phytolon as they innovate in this market." About Ginkgo Bioworks: Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit and read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks), or LinkedIn. About Phytolon: Phytolon is focused on offering natural food colors that comply with the consumers demand for clean label, healthy, and sustainable food systems. Leveraging our novel fermentation-based production technology, we are committed to providing cost-efficient and sustainable solutions, while guaranteeing robust supply to customers around the world. Phytolon's portfolio currently includes multiple shades, covering the purple, pink, red, orange, and yellow spectrum, targeting multiple food categories in the food and beverage market To learn more, visit and follow us on our LinkedIn. Forward-Looking Statements of Ginkgo Bioworks This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's cell programming platform. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to realize near-term and long-term cost savings associated with our site consolidation plans, including the ability to terminate leases or find sub-lease tenants for unused facilities, (ii) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (iii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, including with respect to our solutions and tools offerings, (iv) the risk of downturns in demand for products using synthetic biology, (v) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vi) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vii) the outcome of any pending or potential legal proceedings against Ginkgo, (viii) our ability to realize the expected benefits from and the success of our Foundry platform programs and Codebase assets, (ix) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, (x) the product development, production or manufacturing success of our customers, (xi) our exposure to the volatility and liquidity risks inherent in holding equity interests in other operating companies and other non-cash consideration we may receive for our services, (xii) the potential negative impact on our business of our restructuring or the failure to realize the anticipated savings associated therewith and (xiii) the uncertainty regarding government budgetary priorities and funding allocated to government agencies. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 25, 2025 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations. PHYTOLON MEDIA CONTACT:Shir Haitshir@ GINKGO BIOWORKS INVESTOR CONTACT:investors@ GINKGO BIOWORKS MEDIA CONTACT:press@ View original content to download multimedia: SOURCE Ginkgo Bioworks
